摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)methanol | 1527473-36-4

中文名称
——
中文别名
——
英文名称
(3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)methanol
英文别名
[3-[4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl]methanol
(3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)methanol化学式
CAS
1527473-36-4
化学式
C19H22N4O
mdl
——
分子量
322.41
InChiKey
JMOMEVFJRJVJNY-ZDUSSCGKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    65
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    5-溴-4-氯-7H-吡咯并[2,3-d]嘧啶 在 bis-triphenylphosphine-palladium(II) chloride 、 lithium hydroxide monohydrate 、 sodium carbonate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下, 以 异丙醇丙酮乙腈正丁醇 为溶剂, 反应 52.25h, 生成 (3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)methanol
    参考文献:
    名称:
    [EN] NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
    [FR] NOUVELLES 7H-PYRROLO[2,3-D]PYRIMIDINES SUBSTITUÉES PAR UN GROUPE AMINO EN POSITION 4, UTILISÉES COMME INHIBITEURS DE LRRK2
    摘要:
    本发明提供了新型的Formula I的4,5-二取代-7H-吡咯并[2,3-c/]嘧啶衍生物,以及其药学上可接受的盐,其中R1、R2、R3、R4和R5如规范中所定义。该发明还涉及包括Formula I化合物的药物组合物,以及利用这些化合物治疗与LRRK2相关的疾病,如神经退行性疾病,包括帕金森病或阿尔茨海默病,癌症,克罗恩病或麻风病。
    公开号:
    WO2014001973A1
点击查看最新优质反应信息

文献信息

  • Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors
    申请人:Pfizer Inc.
    公开号:US20140005183A1
    公开(公告)日:2014-01-02
    The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    本发明提供了一种新型的4,5-二取代-7H-吡咯并[2,3-d]嘧啶衍生物I式,以及其药学上可接受的盐,其中R1、R2、R3、R4和R5如规范所定义。本发明还涉及含有I式化合物的制药组合物,以及用于治疗与LRRK2相关的疾病,如神经退行性疾病,包括帕金森病或阿尔茨海默病,癌症,克隆病或麻风病的化合物的用途。
  • 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors
    申请人:Pfizer Inc.
    公开号:US09156845B2
    公开(公告)日:2015-10-13
    The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    本发明提供了新型的4,5-二取代-7H-吡咯并[2,3-d]嘧啶衍生物I的药物可接受盐,其中R1、R2、R3、R4和R5在规范中定义。本发明还涉及包括式I化合物的制药组合物,并将该化合物用于治疗与LRRK2相关的疾病,如神经退行性疾病,包括帕金森病或阿尔茨海默病,癌症,克隆病或麻风病。
  • Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors
    申请人:Pfizer Inc.
    公开号:US20150366874A1
    公开(公告)日:2015-12-24
    The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    本发明提供了新型的4,5-二取代-7H-吡咯并[2,3-d]嘧啶衍生物I式及其药物可接受的盐,其中R1、R2、R3、R4和R5如规范中所定义。本发明还涉及包括I式化合物的制药组合物以及在治疗与LRRK2相关的疾病,如神经退行性疾病(包括帕金森病或阿尔茨海默病)、癌症、克罗恩病或麻风病中使用该化合物的用途。
  • NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS
    申请人:Pfizer Inc.
    公开号:EP2867236B1
    公开(公告)日:2017-06-14
  • US9156845B2
    申请人:——
    公开号:US9156845B2
    公开(公告)日:2015-10-13
查看更多